ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Ranitidine Cancer Lawsuits Move Forward in Florida After Months of Zantac Recalls

Zantac

On Feb. 6, 2020, federal judges approved the transfer of 15 Zantac-related lawsuits to a South Florida court. Consumers allege that batches of the popular heartburn relief medication are contaminated with a carcinogen, causing its users to develop cancer.

The consolidation of cases is known as a multidistrict litigation, or MDL, and it is a management procedure used to streamline pretrial and discovery processes.

It also allows potentially thousands of additional Zantac-related lawsuits to join the litigation.

According to the transfer order, another 126 cases are pending in 21 districts nationwide.

Litigation within the MDL is only expected to grow.

A Sept. 13, 2019 announcement by the U.S. Food and Drug Administration confirmed the presence of trace amounts of a potential cancer-causing chemical in Zantac and its generic counterpart, ranitidine.

A series of voluntary recalls of the drug followed.

Soon after, consumers began filing lawsuits against international drug companies including Sanofi, Boehringer Ingelheim Pharmaceuticals and Pfizer.

The newly formed MDL contains both individual cases alleging personal injuries and putative class actions seeking refunds and other economic damages.

Personal injury cases claim that consumers contracted liver, bladder and other types of cancer as a result of ranitidine contamination with a chemical known as N-nitrosodimethylamine, or NDMA. While Zantac may cause other side effects, those are not part of these lawsuit claims.

Consumers also accuse ranitidine manufacturers, sellers and distributors of knowing that the medications exposed users to NDMA and hiding these dangers from the public.

All legal proceedings for the MDL will take place in the U.S. District Court for the Southern District of Florida.

The defendant drug companies initially sought to centralize the MDL in other courts, including New Jersey, where Zantac distributor Sanofi is headquartered.

“At oral argument, however, most plaintiffs appeared to have coalesced around the Southern District of Florida as their first choice for transferee district,” the transfer order stated.

U.S. District Judge Robin Rosenberg will preside over the new MDL, No. 2924. This is Rosenberg’s first time overseeing an MDL.

Once discovery is complete, the judge may select several individual lawsuits to proceed as bellwether trials.

These initial trials help both sides predict how other suits in the MDL may fare. For example, if drug companies lose most of the bellwether trials, they may reach a global settlement with consumers more quickly.

Were you diagnosed with bladder or stomach cancer after taking Zantac? Get a Free Case Review

Lawsuits Stem from NDMA Cancer Concerns

NDMA is a man-made chemical with no district color. According to the Environmental Protection Agency, animals exposed to the chemical have developed tumors in the liver, blood vessels, kidneys and respiratory tract.

This is why the chemical is classified by the FDA as a probable human carcinogen, or a substance that could cause cancer.

Concerns over Zantac began last year when Valisure, an online pharmacy, discovered NDMA in batches of ranitidine during routine independent testing.

In a Sept. 9, 2019 FDA citizens petition letter, Valisure claimed that it detected extremely high levels of the chemical in every lot it tested across multiple manufacturers.

According to the company’s data, one tablet of Zantac may contain amounts of NDMA several thousand times higher than acceptable FDA limits.

The petition also noted that ranitidine has been implicated as a cause of NDMA formation by multiple research groups, including those at Stanford University.

The FDA has since posted test results of ranitidine samples on its website and asked companies to conduct their own laboratory testing.

In January, California-based laboratory Emery Pharma noted that prolonged heat exposure can increase NDMA to unsafe levels in ranitidine.

“This was concerning, since significantly elevated temperatures can occur within closed vehicles during transportation and during storage of the drug,” the company stated in a Jan. 2, 2020 letter to the FDA.

The FDA maintains that it does not have enough scientific evidence to recommend whether consumers should continue or stop taking ranitidine medicines at this time. Agency investigations are ongoing.

Zantac Contamination Shares Similarities and Differences with Valsartan Recalls

News of contaminated Zantac products spurred Walmart, Walgreens, CVS and Rite Aid to pull prescription and over-the-counter varieties of the drug from their shelves.

Voluntary recalls of the drug by Sanofi and other companies have also taken place.

Ranitidine is not the first drug to contain a nitrosamine impurity. High levels of the chemical were discovered in batches of several valsartan blood pressure medications that prompted a voluntary FDA recall in July 2018. A series of lawsuits soon followed, and judges eventually consolidated cases into an MDL.

But unlike Valsartan lawsuits — in which consumers blame faulty manufacturing for contamination — plaintiffs in Zantac-related suits allege that NDMA is inherent to the drug’s molecular structure.

For this reason, attorneys expect the Zantac litigation to “almost certainly dwarf” the Valsartan MDL, according to court documents.

In an email, plaintiff attorney Robert Hilliard of Hilliard Martinez Gonzales told Drugwatch that his firm has already been hired by 15,000 consumers.

“Zantac will ultimately be one of the biggest consumer frauds ever perpetrated by Big Pharma,” wrote Hilliard, who said he believes consumer claims are backed by strong scientific evidence.

  •  
  •  
  •  
Sophia Clifton, editor at Drugwatch.com
Written By Sophia Clifton Editor

12 Cited Research Articles

Drugwatch.com writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Agency for Toxic Substances and Disease Registry. (1989, December). Toxicological profile for nNitrosodimethylamine. Retrieved from https://www.atsdr.cdc.gov/ToxProfiles/tp141-c1-b.pdf
  2. Environmental Protection Agency. (2016, September). N-Nitrosodimethylamine Hazard Summary. Retrieved from https://www.epa.gov/sites/production/files/2016-09/documents/n-nitrosodimethylamine.pdf
  3. Light, D. and Kucera, K. (2019, September 9). Re: Valisure Citizen Petition on Ranitidine. Retrieved from https://www.valisure.com/wp-content/uploads/Valisure-Ranitidine-FDA-Citizen-Petition-v4.12.pdf
  4. Mitch, W. and Zeng, T. (2016, March 18). Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine. Retrieved from https://aboutlawsuits-wpengine.netdna-ssl.com/wp-content/uploads/2019-11-04-Motion.pdf
  5. Najafi, R. (2020, January 2). Re: Emery Pharma Citizen Petition. Retrieved from https://emerypharma.com/wp-content/uploads/2020/01/EP-Ranitidine-FDA-Citizen-Petition-v21-January-2-2020.pdf
  6. U.S. Food and Drug Administration. (2019, November 1). Laboratory analysis of ranitidine and nizatidine products. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine
  7. U.S. Judicial Panel on Multidistrict Litigation. (2020, January 29). Supplemental Interested Party Response in Support of Motion for Transfer of Actions Pursuant to 28 U.S.C. § 1407 for Coordinated or Consolidated Pretrial Proceeding; In re Zantac/Ranitidine NDMA Litigation. Retrieved from https://pacer.uscourts.gov/
  8. U.S. Judicial Panel on Multidistrict Litigation. (2019, November 4). Brief in support of plaintiffs’ motion for transfer of actions to the District of New Jersey pursuant to 28 U.S.C. § 1407 for coordinated or consolidated pretrial proceedings; In re Zantac/Ranitidine NDMA Litigation. Retrieved from https://aboutlawsuits-wpengine.netdna-ssl.com/wp-content/uploads/2019-11-04-Motion.pdf
  9. U.S. Judicial Panel on Multidistrict Litigation. (2019, November 27). Defendants Boehringer Ingelheim, GSK, Pfizer and Sanofi’s response to motion for transfer and consolidation under 28 U.S.C. 1407; In re Zantac/Ranitidine NDMA Litigation. Case MDL No. 2924 Document 72. Retrieved from https://www.bloomberglaw.com/public/desktop/document/INREZantacRanitidineProductsLiabilityLitigationDocketNo2924USJPML/3?1580389466
  10. U.S. Judicial Panel on Multidistrict Litigation. (2020 February 6). Transfer order: In re Zantac/Ranitidine NDMA Litigation. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/MDL-2924-Transfer%20Order-1-20.pdf
  11. Woodcock, J. (2019, September 13). Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. Retrieved from https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine
  12. World Health Organization. (2008). N-Nitrosodimethylamine in drinking-water: Background document for preparation of WHO guidelines for drinking-water quality. Retrieved from https://www.who.int/water_sanitation_health/dwq/chemicals/ndmasummary_2ndadd.pdf
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's sponsors support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(855) 818-6938